Last reviewed 2026-05-27 · How we verify

BUCRICAINE

Phase 2 active Small molecule ✓ Verified May 2026

BUCRICAINE is a bucricaine drug. It is currently in Phase 2 development for Local anesthesia.

Bucricaine works by blocking sodium channels in nerve cells, preventing the transmission of pain signals.

Bucricaine is a small molecule drug in the bucricaine class, used for local anesthesia. Its exact target is unknown, but it is effective in numbing specific areas of the body. Bucricaine is approved for use in local anesthesia, but its commercial status and regulatory approvals are unclear. As a local anesthetic, bucricaine works by blocking nerve signals, preventing pain and discomfort. Further information on its pharmacokinetics and safety profile is needed.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUCRICAINE
Drug class	bucricaine
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Imagine your nerves are like electrical wires, carrying signals to and from your brain. Bucricaine blocks these wires, stopping the pain signals from getting through. This numbs the area, making it less sensitive to pain.

Approved indications

Local anesthesia

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BUCRICAINE CI brief — competitive landscape report
BUCRICAINE updates RSS · CI watch RSS

Frequently asked questions about BUCRICAINE

What is BUCRICAINE?

BUCRICAINE is a bucricaine drug, indicated for Local anesthesia.

How does BUCRICAINE work?

Bucricaine works by blocking sodium channels in nerve cells, preventing the transmission of pain signals.

What is BUCRICAINE used for?

BUCRICAINE is indicated for Local anesthesia.

What drug class is BUCRICAINE in?

BUCRICAINE belongs to the bucricaine class. See all bucricaine drugs at /class/bucricaine.

What development phase is BUCRICAINE in?

BUCRICAINE is in Phase 2.

Drug class: All bucricaine drugs
Therapeutic area: All drugs in Pain
Indication: Drugs for Local anesthesia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing